Insight Molecular Diagnostics Inc. — Director's Dealing 2021

May 24, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-05-18

Reporting Person: Yu Li (VP Cntrllr/Prncpl Acctng Offcr)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Units	$		Common Stock (25000)		Direct

Footnotes

F1: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant.

F2: Grant of restricted stock units under the OncoCyte 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock.